The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs

doi:10.1016/0006-2952(93)90064-4

Biochemical Pharmacology

Volume 45, Issue 2, 26 January 1993, Pages 295-301

https://doi.org/10.1016/0006-2952(93)90064-4 Get rights and content

Abstract

The expression of human UDP-glucuronosyltransferase (UGT) 1 gene family in the liver and kidney was examined using specific enzyme activity, antibodies and DNA probes for each of the four family members. Phenol UGT HP1 was expressed at a similar, relatively low, abundance in each liver and kidney whereas phenol UGT HP4 was more highly expressed in the kidney. Bilirubin UGTs (HP2 and HP3) were not detectable in the kidney and HP3 was the major isoform in the liver. The UGT activities towards certain specific substrates correlated well with the respective mRNA levels in the tissues. Bilirubin UGT HP3 was induced 2–3-fold in the livers from patients treated with phenytoin and phenobarbital. Storage of a human liver in University of Wisconsin solution which contains dexamethasone and insulin caused a large accumulation of all the UGT mRNAs, but these were not quantitatively translated into expressed UGT activities. The implications of these results are discussed.

References (29)

B Burchell et al.
The UDP-glucuronosyltransferases
J Pharmacol Ther
(1989)
S Fournel-Gigleux et al.
Expression of a human liver cDNA encoding hyodeoxycholic acid UDP-glucuronosyltransferase in cell culture
FEBS Lett
(1989)
JK Ritter et al.
Cloning and expression of human liver UDP-glucuronosyltrans- ferase in COS-1 cells
J Biol Chem
(1990)
L Sutherland et al.
Characterisation of a human bilirubin UDP-glucuronosyltransferase stably expressed in hamster lung fibroblast cell cultures
FEBS Lett
(1992)
JK Ritter et al.
A novel complex locus UGT1 encodes human bilirubin, phenol and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini
J Biol Chem
(1992)
M Barry et al.
Enzyme induction and inhibition
Pharmacol Ther
(1990)
AP Feinberg et al.
A technique for labelling DNA restriction fragments to high specific activity
Anal Biochem
(1983)
G Otani et al.
UDP-glucuronyltransferase in perfused rat liver and in microsomes III. Effects of galactosamine and carbon tetrachloride on the glucuronidation of 1-naphthol and bilirubin
Pharmacology
(1976)
SK Bansal et al.
A unified method for the assay of uridine diphosphoglucuronyl-transferase activities towards various aglycones using uridine diphospho-[U-¹⁴C]glucuronic acid
Anal Biochem
(1980)
BL Coffman et al.
Characterisation and primary sequence of a human hepatic microsomal estriol UDP-glucuronoyltransferase
Arch Biochem Biophys
(1990)

JS He et al.

A barbiturate-regulated protein binding to a common sequence in the cytochrome P450 genes of rodents and bacteria

J Biol Chem

(1991)

DH Harding et al.

Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells

MR Jackson et al.

Cloning of a human liver microsomal UDP-glucuronosyltransferase cDNA

Biochem J

(1987)

D Harding et al.

Cloning of human UDP-glucuronosyltransferase cDNAs

Cited by (94)

Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion
2017, British Journal of Anaesthesia
In our preliminary study, the modified Marsh (M-Marsh) model caused an inadvertent underdosing of propofol in underweight patients. However, the predictive performance of the M-Marsh and Schnider models incorporated in commercially available target-controlled infusion (TCI) pumps was not evaluated in underweight patients.
Thirty underweight patients undergoing elective surgery were randomly allocated to receive propofol via TCI using the M-Marsh or Schnider models. The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 μg ml⁻¹. Arterial blood samples were obtained at least 7 min after achieving each pseudo-steady-state.
A total of 172 plasma samples were used to determine the predictive performance of both models. The pooled median (95% confidence interval) biases and inaccuracies at a target Ce ≤ 3 μg ml⁻¹ were −22.6 (−28.8 to −12.6) and 31.9 (24.8–36.8) for the M-Marsh model and 9.0 (1.7–16.4) and 28.5 (21.7–32.8) for the Schnider model, respectively. These values at Ce ≥ 4 μg ml⁻¹ were −9.6 (−16.0 to −6.0) and 24.7 (21.1–27.9) for the M-Marsh model and 19.8 (12.9–25.7) and 36.2 (31.4–39.7) for the Schnider model, respectively.
The pooled biases and inaccuracies of both models were clinically acceptable. However, the M-Marsh and Schnider models consistently produced negatively and positively biased predictions, respectively, in underweight patients. In particular, the M-Marsh model showed greater inaccuracy at target Ce≤3 μg ml⁻¹ and the Schnider model showed greater inaccuracy at target Ce ≥ 4 μg ml⁻¹. Therefore, it is necessary to develop a new pharmacokinetic model for propofol in underweight patients.
KCT0001502.
Effects of nifedipine on the pharmacokinetics of repaglinide in rats: Possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine
2013, Pharmacological Reports
The aim of this study was to investigate the effects of nifedipine on the bioavailability and pharmacokinetics of repaglinide in rats.
The effect of nifedipine on P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4 activity was evaluated. The pharmacokinetic parameters of repaglinide and blood glucose concentrations were also determined in rats after oral (0.5 mg/kg) and intravenous (0.2 mg/kg) administration of repaglinide to rats in the presence and absence of nifedipine (1 and 3 mg/kg).
Administration of nifedipine resulted in inhibition CYP3A4 activity with an IC₅₀ value of 7.8 μM, and nifedipine significantly inhibited P-gp activity in a concentration-dependent manner. Compared to the oral control group, nifedipine significantly increased the area under the plasma concentration-time curve (AUC_0–∞) and the peak plasma concentration (C_max) of repaglinide by 49.3 and 25.5%, respectively. Nifedipine significantly decreased the total body clearance (CL/F) of repaglinide by 22.0% compared to the oral control group. Nifedipine also increased the absolute bioavailability (AB) of repaglinide by 50.0% compared to the oral control group (33.6%). In addition, the relative bioavailability (RB) of repaglinide was 1.16- to 1.49-fold greater than that of the control group. Compared to the intravenous control, nifedipine significantly increased AUC_0–∞ of repaglinide. Blood glucose concentrations had significant differences compared to the oral control groups.
Nifedipine enhanced the oral bioavailability of repaglinide, which may be mainly attributable to inhibition of CYP3A4-mediated metabolism of repaglinide in the small intestine and/or in the liver and to inhibition of the P-gp efflux transporter in the small intestine and/or reduction of total body clearance by nifedipine. The current study has raised awareness of potential drug interactions by concomitant use of repaglinide with nifedipine.
Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: A possible role of P-glycoprotein and CYP3A4 inhibition by baicalein
2011, Pharmacological Reports
Citation Excerpt :
Nimodipine is metabolized by CYP3A4 in both the liver and small intestine [23, 26] and the absorption of nimodipine in the intestinal mucosa is inhibited by the P-glycoprotein efflux pump [24]. P-glycoprotein is expressed with the glutathione-S-transferases CYP3A4 [29, 31], which may play a synergistic function in regulating the bioavailability of many orally ingested compounds. In the small intestine, P-glycoprotein co-localized with CYP3A4 at the apical membrane of cells [35].
The reduced bioavailability of nimodipine after oral administration might not only be due to the metabolizing enzyme cytochrome P450 3A4(CYP3A4) but also to the P-glycoprotein efflux transporter in the small intestine. The aim of this study was to investigate the effects of baicalein on the pharmacokinetics of nimodipine in rats. The effect of baicalein on P-glycoprotein and CYP3A4 activity was evaluated. A single dose of nimodipine was administered intravenously (3 mg/kg) and orally (12 mg/kg) to rats in the presence and absence of baicalein (0.4, 2 and 8 mg/kg). Baicalein inhibited CYP3A4 enzyme activity in a concentration-dependent manner, with a 50% inhibition concentration (IC₅₀) of 9.2 µM. In addition, baicalein significantly enhanced the cellular accumulation of rhodamine-123 in MCF-7/ADR cells overexpressing P-glycoprotein. Baicalein significantly altered the pharmacokinetics of orally administered nimodipine. Compared to the oral control group given nimodipine alone, the area under the plasma concentration-time curve (AUC_0–∞) and the peak plasma concentration (C_max) of nimodipine significantly increased (p < 0.05 for 2 mg/kg; p < 0.01 for 8 mg/kg). Consequently, the absolute bioavailability of nimodipine in the presence of baicalein (2 and 8 mg/kg) was 31.0–35.3%, which was significantly enhanced (p < 0.05 for 2 mg/kg; p < 0.01 for 8 mg/kg) compared to the oral control group (22.3%). Moreover, the relative bioavailability of nimodipine was 1.39- to 1.58-fold greater than that of the control group. The pharmacokinetics of intravenous nimodipine were not affected by baicalein in contrast to those of oral nimodipine. Baicalein significantly enhanced the oral bioavailability of nimodipine, which may be mainly due to inhibition of the CYP3A4-mediated metabolism of nimodipine in the small intestine and/or in the liver and the inhibition of the P-glycoprotein efflux pump in the small intestine by baicalein. The increase in oral bioavailability of nimodipine in the presence of baicalein should be taken into consideration as a potential drug interaction between nimodipine and baicalein.
Renal Xenobiotic Metabolism
2010, Comprehensive Toxicology, Second Edition
All of the common drug-metabolizing enzymes involved in phase 1 and phase 2 metabolism of xenobiotics are present in the kidney, although the catalytic activity of the various enzymes in the whole kidney is lower than that in the liver. Renal drug-metabolizing enzymes are, however, not evenly distributed along the nephron; cytochrome’s P450 and enzymes involved in conjugation with glutathione (GSH), glucuronic acid, or sulfate are present at much higher concentrations in cells of the proximal tubule than in other parts of the nephron, and thus comparison on a whole organ basis underestimates renal cell activity. Hence, the proximal tubule is the principal site of xenobiotic biotransformation and is particularly susceptible to chemical insult, while the localization of prostaglandin H-synthase (PHS) to the inner medulla and papilla may be a contributory factor to the toxicity produced by chemicals in this part of the nephron.
Many xenobiotic-biotransformation enzymes have been cloned and sequenced, and their presence in the kidney detected. Most of the major families of cytochrome P450 involved in xenobiotic metabolism have been detected in the kidneys of experimental animals and humans. Members of the CYP2B subfamily appear to be absent from rat and mouse kidney but present in the rabbit and hamster. The CYP4A subfamily involved in ω and ω–1 oxidation of fatty acids and arachidonic acid (AA) are expressed at particularly high levels in the kidney and are involved in the side chain metabolism of many drugs and xenobiotics. Glutathione S-transferases (GSTs) have been most extensively characterized in rat and human kidney, this tissue having a different subunit profile from that of the liver, with a predominance of A (alpha) and P1-1 (pi) classes. Cloning has identified a number of relatively new forms of GSTs, and although these enzymes are mainly located in the cytosol, some are associated with microsomes and mitochondria. The kidney plays a pivotal role in the processing of GSH conjugates to their cysteine conjugates and then mercapturic acids for excretion in urine. The renal enzyme cysteine conjugate β-lyase involved in the bioactivation of haloalkane and haloalkene S-cysteine conjugates has been cloned and sequenced from both rat and human kidney, and is shown to be identical to glutamine transaminase K and kynurenine aminotransferase. Cloning approaches have also demonstrated the presence in the kidney of multiple forms of UDP-glucuronosyltransferase, flavin monooxygenase, carboxylesterase, and sulfotransferase
The presence and localization of xenobiotic biotransformation enzymes in human kidney are still limited, although information on embryonic and fetal tissue is beginning to emerge. Many of the enzymes discussed, in addition to their ability to metabolize drugs or foreign compounds, have endogenous functions in the kidney, for instance, in the regulation of salt and water balance, the control of blood pressure and inflammation, and the synthesis of vitamin D.
In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway
2008, Biochemical Pharmacology
Citation Excerpt :
Importantly, both UGT1A and UGT2B7 enzymes are known to be expressed in kidney cortex and medulla, including the proximal and distal convoluted tubules, the loops of Henle, and the collecting ducts [11]. Moreover, glucuronidation activity by human renal tissue has been demonstrated towards numerous xenobiotics and endogenous compounds [11–20]. Despite the widespread use of FSM and its clinical utilization over four decades, the comparative roles of kidney and liver in human FSM glucuronidation appear not to have been characterised.
In order to gain insights into the renal and hepatic glucuronidation of frusemide (FSM), this study: (i) characterised the kinetics of FSM glucuronidation by human liver microsomes (HLM) and human kidney cortical- (HKCM) and medullary- (HKMM) microsomes, and (ii) identified the human UDP-glucuronosyltransferase enzyme(s) involved in this pathway. HLM, HKCM and HLMM efficiently glucuronidated FSM. FSM glucuronide (FSMG) formation followed Michaelis–Menten kinetics in all tissues. While the mean K_m for FSMG formation by HKMM (386 ± 68 μM) was lower than the K_m values for HLM (988 ± 271 μM) and HKCM (704 ± 278 μM), mean V_max/K_m values were comparable for the three tissues. A panel of recombinant UGT enzymes was screened for the capacity to glucuronidate FSM. UGT 1A1, 1A3, 1A6, 1A7, 1A9, 1A10 and 2B7 metabolised FSM. Of the renally and hepatically expressed enzymes, comparison of kinetic parameters suggests a predominant role of UGT1A9 in FSM glucuronidation, although UGT1A1 may also contribute to FSMG formation by HLM. Consistent with these observations, the UGT1A selective inhibitors phenylbutazone and sulfinpyrazone decreased FSMG formation by HLM, HKCM and HKMM by 60–80%, whereas the UGT2B7 selective inhibitor fluconazole reduced FSM glucuronidation by ≤20%. The ability of HKCM and HKMM to form FSMG supports the proposition that the kidney is the main organ involved in FSM glucuronidation in vivo, although a role for hepatic metabolism remains a possibility in renal dysfunction. The data further demonstrate the potential importance of both the medulla and cortex in renal drug metabolism and detoxification.
Rewiring of Drug Metabolism and Its Cross-talk with Metabolic Reprogramming in Cancer
2022, DRUG METABOLISM HANDBOOK: CONCEPTS AND APPLICATIONS IN CANCER RESEARCH

View all citing articles on Scopus

View full text

The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs

Abstract

J Pharmacol Ther

FEBS Lett

J Biol Chem

FEBS Lett

J Biol Chem

Pharmacol Ther

Anal Biochem

Pharmacology

Anal Biochem

Arch Biochem Biophys

J Biol Chem

Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells

Cloning of a human liver microsomal UDP-glucuronosyltransferase cDNA

Biochem J

Cloning of human UDP-glucuronosyltransferase cDNAs